DNR

DRUG2 trials

Sponsors

University of California, San Diego, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions

Acute Lymphocytic LeukemiaAdult Acute Lymphoblastic LeukemiaAdult Lymphoblastic Lymphoma

Phase 2

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

TerminatedNCT02043587

University of California, San DiegoAcute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma

Start: 2014-01-31End: 2022-04-14Updated: 2022-05-02

Unknown Phase

Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Adult Acute Lymphoblastic Leukemia

Start: 2013-10-10End: 2019-06-30Target: 40Updated: 2018-02-05

Related Papers

A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401

Blood2018-11-297 citations